Chemoimmunotherapy Can Restrict Metastasis Of Breast Cancer, Study

In a recent study conducted at the René Huguenin Cancer Centre in Saint Cloud, France, clinicians found that chemoimmunotherapy is absolutely useful for patients suffering from metastatic breast carcinoma. The researchers used Immutep S.A.’s lead product, IMP321, and first-line paclitaxel for their clinical trial and demonstrated clinical benefit in 90 % of patient with metastatic breast cancer. It was an open-label, fixed-dose-escalation trial. Other cancer centers contributing in the study were Tenon Hospital and the Georges Pompidou European Hospital in Paris. The immuno-monitoring for patients was the responsibility of Immutep at its laboratories near Paris.